Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) insider Paul Moore sold 39,741 shares of the stock in a transaction on Friday, November 13th. The shares were sold at an average price of $26.07, for a total value of $1,036,047.87. Following the completion of the sale, the insider owned 33,756 shares in the company, valued at approximately $880,018.92. This trade represents a 54.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Zymeworks Trading Up 0.8%
ZYME opened at $26.45 on Tuesday. The stock’s fifty day simple moving average is $27.26 and its 200 day simple moving average is $25.50. Zymeworks Inc. has a 1-year low of $21.52 and a 1-year high of $31.97. The stock has a market cap of $1.83 billion, a PE ratio of 50.87 and a beta of 1.32.
Zymeworks (NASDAQ:ZYME – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The firm had revenue of $512.92 million during the quarter, compared to analysts’ expectations of $227.40 million. During the same period in the previous year, the business posted ($0.26) earnings per share. The company’s revenue for the quarter was up 828.7% compared to the same quarter last year. Equities analysts forecast that Zymeworks Inc. will post 1.31 earnings per share for the current year.
Zymeworks declared that its Board of Directors has authorized a stock buyback plan on Monday, November 16th that authorizes the company to buy back $200 million in shares. This repurchase authorization authorizes the company to repurchase up to 10.9% of its shares through open market purchases. Share repurchase plans are usually a sign that the company’s management believes its shares are undervalued.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its stake in shares of Zymeworks by 102.7% in the third quarter. Goldman Sachs Group Inc. now owns 954,409 shares of the company’s stock valued at $25,282,000 after acquiring an additional 483,587 shares in the last quarter. Entropy Technologies LP bought a new position in Zymeworks during the third quarter worth about $220,000. Jump Financial LLC increased its position in Zymeworks by 799.1% during the third quarter. Jump Financial LLC now owns 230,236 shares of the company’s stock worth $6,099,000 after acquiring an additional 204,628 shares during the period. HighVista Strategies LLC raised its stake in Zymeworks by 4.6% in the 3rd quarter. HighVista Strategies LLC now owns 35,578 shares of the company’s stock worth $942,000 after purchasing an additional 1,565 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in Zymeworks by 759.9% in the 3rd quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock worth $16,122,000 after purchasing an additional 537,837 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.
Wall Street Analysts Forecast Growth
ZYME has been the subject of several research analyst reports. Truist Financial lifted their target price on shares of Zymeworks from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Stifel Nicolaus set a $46.00 price target on shares of Zymeworks in a report on Friday, August 7th. TD Cowen raised their price objective on shares of Zymeworks from $34.00 to $39.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. B. Riley Financial restated a “buy” rating and set a $44.00 price objective (up from $40.00) on shares of Zymeworks in a research report on Monday, August 10th. Finally, HC Wainwright boosted their price objective on Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zymeworks has an average rating of “Moderate Buy” and an average target price of $43.25.
Get Our Latest Analysis on Zymeworks
About Zymeworks
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
See Also
- Five stocks we like better than Zymeworks
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
